CGT · PD-1 / PD-L1

36개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved36 programs
CGTCurated CoreFDAIovance BiotherapeuticsApproved

lifileucel (Amtagvi, LN-144, tumor infiltrating lymphocyte)

Unresectable or metastatic melanoma after PD-1 blockade · Polyclonal tumor neoantigens (TIL)

#PolyclonaltumorneoantigensTIL#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 47Status Approved
CGTLimited DatastaleTILT Biotherapeutics Ltd.Phase 1

Oncolytic virus Plus Anti-PD1 and Chemotherapy (Oncolytic virus Plus Anti-PD1 and Chemotherapy)

Pancreatic Cancer · Pancreatic Cancer

#PancreaticCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 8Status Recruiting
CGTLimited DatastaleAllife Medical Science and Tech…Phase 1

pd-1 and DC-NK cells (pd-1 and DC-NK cells)

Solid Tumor · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Active
CGTLimited DatastaleShanghai Cell Therapy Group Co.…Phase 1

αPD1-MSLN-CAR T cells (αPD1-MSLN-CAR T cells)

Colorectal Cancer; Ovarian Cancer · Non-small-cell Lung Cancer

#Non-small-cellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Active
CGTLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

Advanced Breast Cancer; Breast Neoplasm Malignant Female · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

Anti-CTLA-4/PD-1 expressing MUC1-CAR-T (Anti-CTLA-4/PD-1 expressing MUC1-CAR-T)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleJiangsu Topcel-KH Pharmaceutica…Phase 1

Anti-PD1 armored CD19 CAR-T cells (Anti-PD1 armored CD19 CAR-T cells)

Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous aPD-L1 armored anti-CD22 CAR T cells (Autologous aPD-L1 armored anti-CD22 CAR T cells)

Solid Tumor, Adult; Cervical Cancer · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

BCMA-PD1-CART Cell (BCMA-PD1-CART Cell)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

CAR-T combined with PD-1 Knockout T cells (CAR-T combined with PD-1 Knockout T cells)

Advanced Esophageal Cancer · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

CAR-T combining PD-1 Knockout (CAR-T combining PD-1 Knockout)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleThe Pregene (ShenZhen) Biotechn…Phase 1

CAR19 T cells carrying cytoplasmic activated PD-1 (CAR19 T cells carrying cytoplasmic activated PD-1)

Relapsed Non Hodgkin Lymphoma · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleThird Military Medical Universi…Phase 1

CD19 CAR and PD-1 knock out engineered T-cells (CD19 CAR and PD-1 knock out engineered T-cells)

Acute Lymphoblastic Leukemia; Burkitt Lymphoma · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

CD19-PD1-CART Cell (CD19-PD1-CART Cell)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

CTLA-4/PD-1 antibodies expressing mesoCAR-T (CTLA-4/PD-1 antibodies expressing mesoCAR-T)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Advanced Solid Tumor · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1/PD-L1 CAR-T cells (Dual-targeting VEGFR1/PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNingbo Cancer HospitalPhase 2

HerinCAR-PD1 cells (HerinCAR-PD1 cells)

PD-1 Antibody; CAR-T Cells · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active

1 / 2 pages

← PreviousNext →